[Hepatitis C and HIV in Spanish prisons].
Soriano
Vicente
V
González-Lahoz
Juan
J
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D005260:Female; D015658:HIV Infections / Q000453:epidemiology* / Q000635:transmission; D015528:HIV Seroprevalence; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000635:transmission; D006760:Hospitalization; D006779:Hospitals, Public / Q000458:organization & administration; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011329:Prisoners; D011330:Prisons / Q000458:organization & administration; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D016036:Seroepidemiologic Studies; D013030:Spain / Q000453:epidemiology; D015819:Substance Abuse, Intravenous / Q000453:epidemiology
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a